Use of trans-palmitoleate in identifying and treating metabolic disease
The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism.
1. A method of treating diabetes mellitus, insulin resistance, or atherogenic dyslipidemia in a subject comprising administering to the subject a pharmaceutical, nutraceutical or dietary formulation, or dietary supplement, comprising trans-palmitoleate, wherein trans-palmitoleate is at least 6% of total fatty acids present in the formulation.